88466-74-4

Basic information

• Product Name: (S)-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER
• Synonyms: L-1-CBZ-NIPECOTIC ACID;(S)-1-CBZ-PIPERIDINE-3-CARBOXYLIC ACID;(S)-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER;(S)-Cbz-Nip-OH;(S)-1-CBZ-NIPECOTICACID;(3S)-1-[(benzyloxy)carbonyl]piperidine-3-carboxylic acid;(S)-1,3-Piperidinedicarboxylic acid 1-(phenylmethyl) ester;3(S)-N-(Carbobenzyloxy)-3-carboxypiperidine
• CAS NO: 88466-74-4
• Molecular Formula: C₁₄H₁₇NO₄
• Molecular Weight: 263.29
• Mol File: 88466-74-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 100-101℃
• Boiling Point: 443.9°C at 760 mmHg
• Flash Point: 222.3°C
• Appearance: /
• Density: 1.265
• Vapor Pressure: 1.16E-08mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.48±0.20(Predicted)
• CAS DataBase Reference: (S)-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER(88466-74-4)
• EPA Substance Registry System: (S)-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER(88466-74-4)

Safety Data

• Hazardous Substances Data: 88466-74-4(Hazardous Substances Data)

Usage

Uses

(S)-1-Cbz-piperidine-3-carboxylic acid is a useful research chemical compound.

InChI:InChI=1/C14H17NO4/c16-13(17)12-7-4-8-15(9-12)14(18)19-10-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2,(H,16,17)/t12-/m0/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 498-95-3 (S)-nipecotic acid 
• 637337-59-8 (4R)-3-[(2S)-2-({[(benzyloxy)carbonyl]amino}methyl)-5-bromo-1-oxopentyl]-4-(1-methylethyl)-5,5-diphenyloxazolidin-2-one 
• 637337-43-0 (4R)-3-(5-bromo-1-oxopentyl)-4-(1-methylethyl)-5,5-diphenyloxazolidin-2-one 
• 4509-90-4 5-bromovaleroyl chloride 
• 868632-22-8 (4R)-3-({(3S)-1-[(benzyloxy)carbonyl]piperidin-3-yl}carbonyl)-4-(1-methylethyl)-5,5-diphenyloxazolidin-2-one 

Downstream Products

• 174699-11-7 (3S)-Piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester 
• 88495-54-9 (3S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid 
• 498-95-3 (S)-nipecotic acid 
• 1142005-50-2 (S)-3-chlorocarbonyl-piperidine-1-carboxylic acid benzyl ester 
• 1222997-51-4 C₁₅H₂₀N₄O₃S 
• 1394169-80-2 (S)-1-(4-(4-bromophenyl)thiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) piperidine-3-carboxamide 
• 1394169-79-9 (S)-1-(2-(4-chlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)piperidine-3-carboxamide 
• 1394170-06-9 C₁₈H₂₅N₃O₂ 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 193693-67-3 (R)-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}piperidine-3-carboxylic acid 
• 193693-68-4 (S)-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}piperidine-3-carboxylic acid 
• 174759-65-0 (S)-3-({(S)-1-[(S)-3-Benzyloxy-2-(naphthalene-2-sulfonylamino)-propionyl]-pyrrolidin-2-ylmethyl}-carbamoyl)-piperidine-1-carboxylic acid benzyl ester 
• 168050-84-8 (S)-3-({(S)-1-[(S)-3-Methoxycarbonyl-2-(naphthalene-2-sulfonylamino)-propionyl]-pyrrolidin-2-ylmethyl}-carbamoyl)-piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold

Direct inhibition of coagulation factor Xa (FXa) carries significant promise for developing effective and safe anticoagulants. Although a large number of FXa inhibitors have been studied, each can be classified as either possessing a highly flexible or a rigid core scaffold. We reasoned that an intermediate level of flexibility will provide high selectivity for FXa considering that its active site is less constrained in comparison to thrombin and more constrained as compared to trypsin. We studied several core scaffolds including 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid for direct FXa inhibition. Using a genetic algorithm-based docking and scoring approach, a promising candidate 23 was identified, synthesized, and found to inhibit FXa with a Ki of 28 μM. Optimization of derivative 23 resulted in the design of a potent dicarboxamide 47, which displayed a Ki of 135 nM. Dicarboxamide 47 displayed at least 1852-fold selectivity for FXa inhibition over other coagulation enzymes and doubled PT and aPTT of human plasma at 17.1 μM and 20.2 μM, respectively, which are comparable to those of clinically relevant agents. Dicarboxamide 47 is expected to serve as an excellent lead for further anticoagulant discovery.

INHIBITORS OF PROTEIN KINASES

Compounds of general Formula I, wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Methods for the stereoselective synthesis of substituted piperidines

One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will